	US 12,414,966 B2
	Method of treating diabetes with FGF21 and GLP1 double gene-modified cell
Haifeng Duan, Beijing (CN); Binghua Xue, Beijing (CN); Jing Xie, Beijing (CN); and Zhenli Zhang, Beijing (CN)
Assigned to BEIJING JIYUAN BIOLOGICAL TECHNOLOGY CO., LTD., Beijing (CN)
Filed by Beijing Jiyuan Biological Technology Co., Ltd., Beijing (CN)
Filed on Jul. 24, 2023, as Appl. No. 18/357,639.
Application 18/357,639 is a continuation of application No. 16/954,763, granted, now 11,752,173, previously published as PCT/CN2018/081616, filed on Apr. 2, 2018.
Claims priority of application No. 201711374615.0 (CN), filed on Dec. 19, 2017.
Prior Publication US 2024/0100100 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61P 3/10 (2006.01); C07K 14/50 (2006.01); C07K 14/605 (2006.01); C12N 5/0775 (2010.01)

CPC A61K 35/28 (2013.01) [A61P 3/10 (2018.01); C07K 14/50 (2013.01); C07K 14/605 (2013.01); C07K 2319/30 (2013.01); C12N 5/0662 (2013.01); C12N 5/0663 (2013.01); C12N 5/0665 (2013.01)]

19 Claims

1. A method of treating diabetes in a subject in need thereof, the method comprising administering to the subject:

(i) a mesenchymal stem cell that expresses:

(a) a first protein comprising an amino acid sequence that has at least 97.0% sequence identity to the sequence set forth in SEQ ID NO: 2, wherein the first protein exhibits fibroblast growth factor 21 (FGF21) activity, and

(b) a second protein comprising an amino acid sequence that has at least 80% sequence identity to the sequence set forth in SEQ ID NO: 5, wherein the second protein exhibits glucagon-like polypeptide 1 (GLP1) activity; or

(ii) a composition comprising the mesenchymal stem cell and a culture medium.